China Looks To Amend Drug Registration Regulation With Bolar Exemption That Favors Generics
This article was originally published in PharmAsia News
Executive Summary
China FDA released a draft regulation on drug registration that formalizes the “Bolar Exemption,” but the approach taken is unbalanced, according to experts, and would end up favoring generic competitors.
You may also be interested in...
Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”
In a dispute related to Amphastar/Watson’s generic enoxaparin, a Federal Circuit panel takes an expansive view of the “Bolar Amendment” and finds that certain post-approval activities are protected from infringement claims, including quality control batch testing of commercial product. The decision draws a blistering dissent from the appeals court’s chief judge, who warns the ruling will “render manufacturing method patents worthless.”
China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes
SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.